The human blood‐brain barrier glucose transporter (GLUT1) is a glucose transporter of gray matter astrocytes S Morgello, RR Uson, EJ Schwartz, RS Haber Glia 14 (1), 43-54, 1995 | 283 | 1995 |
Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease EJ Schwartz, LA Szczech, MJ Ross, ME Klotman, JA Winston, PE Klotman Journal of the American Society of Nephrology 16 (8), 2412-2420, 2005 | 275 | 2005 |
HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes M Husain, GL Gusella, ME Klotman, IH Gelman, MD Ross, EJ Schwartz, ... Journal of the American Society of Nephrology 13 (7), 1806-1815, 2002 | 171 | 2002 |
32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes J Rappaport, YY Cho, H Hendel, EJ Schwartz, F Schachter, JF Zagury The Lancet 349 (9056), 922-923, 1997 | 112 | 1997 |
Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines S Blower, EJ Schwartz, J Mills AIDS Rev 5 (2), 113-25, 2003 | 102 | 2003 |
Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes EJ Schwartz, A Cara, H Snoeck, MD Ross, M Sunamoto, J Reiser, ... Journal of the American Society of Nephrology 12 (8), 1677-1684, 2001 | 94 | 2001 |
Critical role for Nef in HIV-1–induced podocyte dedifferentiation M Sunamoto, M Husain, JC He, EJ Schwartz, PE Klotman Kidney international 64 (5), 1695-1701, 2003 | 78 | 2003 |
Pathogenesis of human immunodeficiency virus (HIV)-associated nephropathy EJ Schwartz, PE Klotman Seminars in nephrology 18 (4), 436-445, 1998 | 59 | 1998 |
Predicting the potential individual-and population-level effects of imperfect herpes simplex virus type 2 vaccines EJ Schwartz, S Blower Journal of Infectious Diseases 191 (10), 1734-1746, 2005 | 43 | 2005 |
Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be? EJ Schwartz Mathematical biosciences 212 (2), 180-187, 2008 | 30 | 2008 |
Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations SJ Snedecor, DR Strutton, V Ciuryla, EJ Schwartz, MF Botteman Vaccine 27 (34), 4694-4703, 2009 | 28 | 2009 |
Estimating epidemic parameters: Application to H1N1 pandemic data EJ Schwartz, B Choi, GA Rempala Mathematical biosciences 270, 198-203, 2015 | 27 | 2015 |
Modelling the epidemic spread of an H1N1 influenza outbreak in a rural university town NK Vaidya, M Morgan, T Jones, L Miller, S Lapin, EJ Schwartz Epidemiology & Infection 143 (8), 1610-1620, 2015 | 25 | 2015 |
Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses R Breban, I McGowan, C Topaz, EJ Schwartz, P Anton, S Blower Mathematical Biosciences & Engineering 3 (3), 459-466, 2006 | 25 | 2006 |
Free-virus and cell-to-cell transmission in models of equine infectious anemia virus infection LJS Allen, EJ Schwartz Mathematical biosciences 270, 237-248, 2015 | 23 | 2015 |
Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines EJ Schwartz, EN Bodine, S Blower Human vaccines 3 (6), 231-238, 2007 | 23 | 2007 |
Dynamics of lentiviral infection in vivo in the absence of adaptive immune responses EJ Schwartz, NK Vaidya, KS Dorman, S Carpenter, RH Mealey Virology 513, 108-113, 2018 | 20 | 2018 |
Immune control of equine infectious anemia virus infection by cell-mediated and humoral responses EJ Schwartz, KA Pawelek, K Harrington, R Cangelosi, S Madrid Scientific Research Publishing, 2013 | 17 | 2013 |
Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments PA Anton, FJ Ibarrondo, WJ Boscardin, Y Zhou, EJ Schwartz, HL Ng, ... Vaccine 26 (35), 4617-4623, 2008 | 16 | 2008 |
Understanding virus–host dynamics following EIAV infection in SCID horses SM Ciupe, EJ Schwartz Journal of theoretical biology 343, 1-8, 2014 | 15 | 2014 |